JP2019528306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528306A5 JP2019528306A5 JP2019511610A JP2019511610A JP2019528306A5 JP 2019528306 A5 JP2019528306 A5 JP 2019528306A5 JP 2019511610 A JP2019511610 A JP 2019511610A JP 2019511610 A JP2019511610 A JP 2019511610A JP 2019528306 A5 JP2019528306 A5 JP 2019528306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- insulin
- group
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122568A JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381263P | 2016-08-30 | 2016-08-30 | |
| US62/381,263 | 2016-08-30 | ||
| US201662411032P | 2016-10-21 | 2016-10-21 | |
| US62/411,032 | 2016-10-21 | ||
| PCT/US2017/049137 WO2018044903A1 (en) | 2016-08-30 | 2017-08-29 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122568A Division JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528306A JP2019528306A (ja) | 2019-10-10 |
| JP2019528306A5 true JP2019528306A5 (enExample) | 2020-10-08 |
| JP7173962B2 JP7173962B2 (ja) | 2022-11-16 |
Family
ID=59799505
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511610A Active JP7173962B2 (ja) | 2016-08-30 | 2017-08-29 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2022122568A Active JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A Pending JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122568A Active JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A Pending JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10995146B2 (enExample) |
| EP (1) | EP3506940A1 (enExample) |
| JP (3) | JP7173962B2 (enExample) |
| KR (3) | KR102708864B1 (enExample) |
| CN (2) | CN118236497A (enExample) |
| AU (2) | AU2017321423C1 (enExample) |
| CA (1) | CA3034777A1 (enExample) |
| IL (2) | IL322691A (enExample) |
| MA (1) | MA46089A (enExample) |
| MX (2) | MX385598B (enExample) |
| NZ (1) | NZ750953A (enExample) |
| SG (2) | SG11201901355SA (enExample) |
| WO (1) | WO2018044903A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7173962B2 (ja) | 2016-08-30 | 2022-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| MX2021008797A (es) * | 2019-01-23 | 2022-01-31 | Regeneron Pharma | Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7). |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| US12398202B2 (en) | 2019-09-04 | 2025-08-26 | Apharma | Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance |
| CN113481290B (zh) * | 2021-06-30 | 2022-08-23 | 华南农业大学 | 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用 |
| CN114342875A (zh) * | 2022-01-12 | 2022-04-15 | 吉林大学 | 一种新型妊娠糖尿病动物模型的建立方法 |
| EP4708502A1 (en) | 2023-08-21 | 2026-03-11 | LG Energy Solution, Ltd. | Cell assembly, battery module including same, and method for manufacturing cell assembly |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836308B2 (ja) | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | 抗体の製造方法 |
| US4206199A (en) | 1977-07-22 | 1980-06-03 | Takeda Chemical Industries, Ltd. | Novel glucagon fragment and its derivatives |
| JPS56163456A (en) | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| US4423034A (en) | 1980-10-16 | 1983-12-27 | Toyo Jozo Kabushiki Kaisha | Process for the preparation of antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| PL178685B1 (pl) | 1992-08-28 | 2000-06-30 | Zymogenetics Inc | Cząsteczka DNA kodująca receptor glukagonu lub peptyd receptora glukagonu, konstrukty DNA, komórka gospodarza zawierająca konstrukty DNA, peptyd receptora glukagonu i sposoby wytwarzania receptora glukagonu lub peptydu receptora glukagonu |
| JP2729159B2 (ja) | 1994-10-31 | 1998-03-18 | 日清製粉株式会社 | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7301036B2 (en) | 2003-12-19 | 2007-11-27 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CN1964947A (zh) | 2004-06-04 | 2007-05-16 | 默克公司 | 吡唑衍生物、包含其的组合物及其用法 |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| JP2008505905A (ja) | 2004-07-07 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法 |
| CA2574147A1 (en) | 2004-07-22 | 2006-02-09 | Linda Brockunier | Substituted pyrazoles, compositions containing such compounds and methods of use |
| PL1856090T3 (pl) | 2005-02-11 | 2010-02-26 | Lilly Co Eli | Podstawione pochodne tiofenu jako antagoniści receptora glukagonu, ich wytwarzanie i terapeutyczne zastosowania |
| CN101146762A (zh) | 2005-03-21 | 2008-03-19 | 默克公司 | 取代的芳基和杂芳基衍生物 |
| WO2006104826A2 (en) | 2005-03-30 | 2006-10-05 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| AU2007240315A1 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | GLP-1 compound/glucagon antibody compositions |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2008098244A1 (en) | 2007-02-09 | 2008-08-14 | Metabasis Therapeutics, Inc. | Novel antagonists of the glucagon receptor |
| AR070844A1 (es) | 2008-03-27 | 2010-05-05 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2 |
| CA2724294A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
| US8436015B2 (en) | 2008-09-15 | 2013-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8445538B2 (en) | 2008-12-19 | 2013-05-21 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
| WO2010088061A1 (en) | 2009-01-28 | 2010-08-05 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010093535A1 (en) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010098948A1 (en) | 2009-02-13 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩 |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| EP2758533B1 (en) | 2011-09-20 | 2018-04-11 | Ionis Pharmaceuticals, Inc. | Antisense modulation of gcgr expression |
| US9453073B2 (en) | 2011-12-02 | 2016-09-27 | Eli Lilly And Company | Anti-glucagon antibodies and uses thereof |
| WO2014181229A2 (en) | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| BR112017005110A2 (pt) * | 2014-09-16 | 2018-01-23 | Regeneron Pharma | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. |
| JP7173962B2 (ja) | 2016-08-30 | 2022-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
-
2017
- 2017-08-29 JP JP2019511610A patent/JP7173962B2/ja active Active
- 2017-08-29 US US16/328,935 patent/US10995146B2/en active Active
- 2017-08-29 MX MX2019002437A patent/MX385598B/es unknown
- 2017-08-29 KR KR1020237014250A patent/KR102708864B1/ko active Active
- 2017-08-29 AU AU2017321423A patent/AU2017321423C1/en active Active
- 2017-08-29 MA MA046089A patent/MA46089A/fr unknown
- 2017-08-29 IL IL322691A patent/IL322691A/en unknown
- 2017-08-29 CA CA3034777A patent/CA3034777A1/en active Pending
- 2017-08-29 CN CN202410379157.3A patent/CN118236497A/zh active Pending
- 2017-08-29 NZ NZ750953A patent/NZ750953A/en unknown
- 2017-08-29 CN CN201780065987.7A patent/CN109922831A/zh active Pending
- 2017-08-29 KR KR1020247021936A patent/KR20240110661A/ko not_active Ceased
- 2017-08-29 SG SG11201901355SA patent/SG11201901355SA/en unknown
- 2017-08-29 EP EP17762315.4A patent/EP3506940A1/en active Pending
- 2017-08-29 KR KR1020197008021A patent/KR20190044079A/ko not_active Ceased
- 2017-08-29 WO PCT/US2017/049137 patent/WO2018044903A1/en not_active Ceased
- 2017-08-29 SG SG10201913074WA patent/SG10201913074WA/en unknown
-
2019
- 2019-02-17 IL IL264879A patent/IL264879B1/en unknown
- 2019-02-28 MX MX2021006457A patent/MX2021006457A/es unknown
-
2021
- 2021-04-05 US US17/222,236 patent/US11708416B2/en active Active
-
2022
- 2022-08-01 JP JP2022122568A patent/JP7633213B2/ja active Active
-
2023
- 2023-06-05 US US18/329,358 patent/US12624116B2/en active Active
-
2024
- 2024-09-13 JP JP2024159035A patent/JP2024178249A/ja active Pending
- 2024-12-19 AU AU2024278594A patent/AU2024278594A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2025176106A (ja) | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 | |
| US11884726B2 (en) | Dosage regimen for MAdCAM antagonists | |
| JP2021526534A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| Fan et al. | The use of biological agents in the treatment of rheumatoid arthritis | |
| JP2019528285A5 (enExample) | ||
| JP2023528265A (ja) | Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患の治療方法 | |
| AU2017312049A1 (en) | Methods of treating Crohn's Disease with an anti-NKG2D antibody | |
| JP2024069230A5 (enExample) | ||
| CN102307899A (zh) | 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂 | |
| JP2021502065A5 (enExample) | ||
| CN102834413A (zh) | 代谢障碍的治疗 | |
| TW202235435A (zh) | 抗cd38抗體及其用途 | |
| CN113166238B (zh) | 使用抗体及其片段对免疫检测点抑制剂诱导的腹泻、结肠炎或小肠结肠炎的局部治疗 | |
| Jacobi et al. | Treatment of inflammatory dermatoses by tumour necrosis factor antagonists | |
| JP2022548004A (ja) | オマリズマブを使用した治療方法 | |
| JP2020517648A5 (enExample) | ||
| TW202112373A (zh) | 使用抗cd38抗體之組合療法 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| NZ790260B2 (en) | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling | |
| RU2022112615A (ru) | Способы лечения тяжелой инсулинорезистентности путем прерывания предачи сигнала глюкагонового рецептора |